AI summary · may contain errors
Overall survival in Waldenström macroglobulinemia did not change across diagnosis eras overall (p=0.64), but improved for patients aged <65 years post-2006 (median 18.8 vs 14.1 years, p=0.018).
- Open access
Springer Nature · Oncology · ISSN 0887-6924, 1476-5551
Rebuilt
Newest first · last 60 days
AI summary · may contain errors
Overall survival in Waldenström macroglobulinemia did not change across diagnosis eras overall (p=0.64), but improved for patients aged <65 years post-2006 (median 18.8 vs 14.1 years, p=0.018).
AI summary · may contain errors
In two patient-derived B-cell acute lymphoblastic leukemia cases, clonal barcoding and multiome single-cell profiling show unidirectional differentiation from an immature source cluster into differentiated progeny.
AI summary · may contain errors
In 202 chronic myeloid leukemia patients treated with olverembatinib or ponatinib, the high-burden ASXL1 p.G646Wfs*12 variant is the most consistent genomic marker of inferior responses and outcomes.
AI summary · may contain errors
AML874, a selective CDK8/CDK19 inhibitor, disrupts Mediator-dependent transcription and shows subtype-specific sensitivity in FLT3-mutated AML, with strong synergy to venetoclax.
AI summary · may contain errors
Pathological mesenchymal stromal cells in MDS and sAML induce profound chromatin remodeling in NK cells, suppressing stress-response and survival programs and impairing cytotoxicity.
AI summary · may contain errors
In a retrospective cohort of 151 patients with immune-mediated bone marrow failure syndromes, salvage immunosuppressive therapy—including sirolimus—produced significant response rates with lineage- and disease-state–dependent efficacy.
AI summary · may contain errors
In CALR-mutant myeloproliferative neoplasms, NK cells show preserved degranulation and high TIGIT expression, with TIGIT blockade reducing platelet numbers in a transplant mouse model.
AI summary · may contain errors
Relcobatinib (ELVN-001) shows marked selectivity for BCR::ABL1 and robust anti-tumor activity in a human CML mouse xenograft model as monotherapy and with asciminib.
AI summary · may contain errors
GAK is a tumor-selective dependency in diffuse large B-cell lymphoma, and its kinase activity is required for mitotic progression, with inhibition causing G2/M arrest and cell death.
Journals this month
Topics moving, week to 17 Nov 2026
By field